Company intelligence / Profile preview

Pro Bono Bio

Reading, Berkshire, United Kingdomhtl.london ↗

Ownership: Private
Employees: ~7
Development stage: Commercial

Overview

Pro Bono Bio has commercialized Flexiseq™, a nanotechnology-based topical gel for osteoarthritis pain relief. The company also reported preclinical success with long-lasting subcutaneous formulations of recombinant blood clotting factors VIIa, VIII, and IX targeting haemophilia. Its focus includes both commercial products and early-stage R&D in nanomedicine.

Therapeutic areas: OtherRheumatologyHematology
Modalities: Nanotechnology-based therapeutics and medical devicesTopical gels (e.g., for osteoarthritis)Recombinant blood factors (preclinical/early stage)
Industry: Biotech

Drug pipeline

3 assets

Flexiseq

Commercial

Indications: Osteoarthritis

2 more assets in the full pipeline.

Request access →

Partnerships

RUSNANO (Russian Corporation of Nanotechnologies)Specialist service providers in pharma product development/commercialization.

Beyond the preview

Go deeper on Pro Bono Bio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Pro Bono Bio.

Explore the full profile